Opens in a new tab

press release – price-sensitive

PRICE-SENSITIVE | NON PRICE-SENSITIVE

  • REVENUE AS OF 30 SEPTEMBER 2026 AMOUNTING TO APPROXIMATELY 4.0 MILLION EUROS, AN INCREASE OF 12.7% COMPARED TO THE SAME PERIOD IN 2025

    REVENUE AS OF 30 SEPTEMBER 2026 AMOUNTING TO APPROXIMATELY 4.0 MILLION EUROS, AN INCREASE OF 12.7% COMPARED TO THE SAME…
    Go to the press release

  • THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2026

    THE BOARD OF DIRECTORS HAS APPROVED THE HALF-YEARLY REPORT AS OF 30 JUNE 2026
    Go to the press release

  • FINANCING AND THE AWARD OF FUNDING FOR THE NEX-BIO PROJECT, WORTH 2 MILLION EUROS

    FINANCING AND THE AWARD OF FUNDING FOR THE NEX-BIO PROJECT, WORTH 2 MILLION EUROS
    Go to the press release

  • REVENUE AS OF JUNE 30, 2026, AMOUNTING TO APPROXIMATELY 3.0 MILLION EUROS, AN INCREASE OF APPROXIMATELY 17.7% COMPARED TO THE SAME PERIOD IN 2025

    REVENUE AS OF JUNE 30, 2026, AMOUNTING TO APPROXIMATELY 3.0 MILLION EUROS, AN INCREASE OF APPROXIMATELY 17.7% COMPARED TO THE…
    Go to the press release

  • TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROS

    TURNOVER AS OF MARCH 31, 2026 EQUAL TO APPROXIMATELY 1.6 MILLION EUROS
    Go to the press release

  • SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.

    SHAREHOLDERS’ MEETING OF ARTERRA BIOSCIENCE S.P.A.
    Go to the press release

  • FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,000

    FINANCING AND GRANTING OF FUNDING FOR THE ‘RE-FOOD’ PROJECT IN THE AMOUNT OF €720,000
    Go to the press release

  • PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING

    PUBLICATION OF NOTICE OF CALL FOR ORDINARY SHAREHOLDERS’ MEETING
    Go to the press release

  • THE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 2025

    THE BOARD OF DIRECTORS HAS APPROVED THE DRAFT FINANCIAL STATEMENTS AS OF 31 DECEMBER 2025
    Go to the press release

  • TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN 2024

    TURNOVER AS OF 31 DECEMBER 2025 AMOUNTING TO €4.6 MILLION, AN INCREASE OF 11.42% COMPARED TO THE SAME PERIOD IN…
    Go to the press release

⚠️ ATTENZIONE: ⚠️

Siamo venuti a conoscenza dell’esistenza del sito internet “terrabiomedical.com“, che riproduce fedelmente i contenuti e l’immagine del sito web ufficiale della nostra Società, senza alcuna nostra autorizzazione.

A tal proposito, Arterra Bioscience S.p.A. precisa di essere totalmente estranea al suddetto sito internet, così come a qualsiasi attività, iniziativa o comunicazione riconducibile a una società denominata “Terra North America” e/o alla Sig.ra “Natalia Astor”.

Per qualsiasi informazione, comunicazione o richiesta relativa ad Arterra Bioscience S.p.A., vi invitiamo a fare esclusivo riferimento ai nostri canali ufficiali, consultabili sul sito “www.arterrabio.it”.

Grazie per l’attenzione.

Arterra Bioscience S.p.A.

⚠️ IMPORTANT NOTICE: ⚠️

We have become aware of the existence of the website “terrabiomedical.com”, which reproduces the content and visual identity of our Company’s official website without our knowledge or authorization.

In this regard, Arterra Bioscience S.p.A. hereby states that it has absolutely no connection with the aforementioned website, nor with any activities, initiatives or communications attributable to an entity operating under the name “Terra North America” and/or Ms. “Natalia Astor”.

For any information, communications or enquiries concerning Arterra Bioscience S.p.A., please refer exclusively to our official communication channels, available on our website: “www.arterrabio.it”.

Thank you for your attention.

Arterra Bioscience S.p.A.